Trial Profile

Study of Pd-1 Antibody in Combination with Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms NACI

01 Nov 2024 Status changed from recruiting to active, no longer recruiting.
01 Dec 2023 Results of preliminary analysis of samples from a cervical cancer from this trial demonstrated neoadjuvant chemotherapy induces a state transition to epithelial-immune, which correlates with pathological complete remission following treatment with immune-checkpoint blockade, published in the Nature Genetics.
01 Dec 2023 Results assessing efficacy and safety of neoadjuvant chemo-immunotherapy for locally advanced cervical cancer, published in the Lancet Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com